A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors von Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.

Volltext

Abstract 4647: Tie2-expressing monocytes (TEMs) as potential biomarkers of angiopoietin-Tie2 (Ang/Tie2) directed therapies: correlative analysis of a phase I study of AMG386 + tems... von Cescon, David W., Bedard, Philippe L., Chow, Sue, Chen, Helen, Razak, Albiruni, Wizemann, Monika, Siu, Lillian L., Hedley, David

Volltext

Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041) von Tan, David Shao Peng, Kollmannsberger, Christian K., Hotte, Sebastien J., Cescon, David W., Diaz-Padilla, Ivan, Hedley, David W., Renouf, Daniel John, Razak, Albiruni R.A., Gelmon, Karen A., Hirte, Hal W., Wang, Lisa, Wizemann, Monika, Moscow, Jeffrey, Chen, Helen X., Siu, Lillian L., Bedard, Philippe L.

Volltext